Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
Sebastian Schneeweiß(Brigham and Women's Hospital), Brian Bressler(University of British Columbia), Claire Canning(Brigham and Women's Hospital), Joy Lee(University of Arizona), Daniel H. Solomon(Brigham and Women's Hospital), Joshua R. Korzenik(Harvard University)
Cited by 214
Related Papers
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis
|New England Journal of Medicine|2013|653